Innospec [IOSP] vs Chemours [CC] Detailed Stock Comparison
Innospec
NASDAQ
Loading...
Chemours
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Innospec wins in 11 metrics, Chemours wins in 7 metrics, with 0 ties. Innospec appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Innospec | Chemours | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 102.32 | 67.83 | Chemours |
| Price-to-Book Ratio | 1.53 | 7.58 | Innospec |
| Debt-to-Equity Ratio | 3.79 | 1,818.41 | Innospec |
| PEG Ratio | 12.75 | 5.19 | Chemours |
| EV/EBITDA | 28.64 | 15.01 | Chemours |
| Profit Margin (TTM) | 1.08% | -7.21% | Innospec |
| Operating Margin (TTM) | 7.96% | -12.69% | Innospec |
| EBITDA Margin (TTM) | 7.96% | N/A | N/A |
| Return on Equity | 1.55% | -87.55% | Innospec |
| Return on Assets (TTM) | 0.65% | 0.34% | Innospec |
| Free Cash Flow (TTM) | $122.20M | $-993.00M | Innospec |
| Dividend Yield | 1.97% | 6.82% | Chemours |
| 1-Year Return | -23.47% | -32.67% | Innospec |
| Price-to-Sales Ratio (TTM) | 1.11 | 0.31 | Chemours |
| Enterprise Value | $1.77B | $5.64B | Chemours |
| EV/Revenue Ratio | 0.99 | 0.96 | Chemours |
| Gross Profit Margin (TTM) | 28.02% | 17.21% | Innospec |
| Revenue per Share (TTM) | $72 | $39 | Innospec |
| Earnings per Share (Diluted) | $0.78 | $-2.74 | Innospec |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Innospec vs Chemours Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Innospec | 2.04% | 3.68% | -8.27% | -12.81% | -26.62% | -24.34% |
| Chemours | 0.08% | 6.00% | -10.56% | 8.45% | -32.16% | -27.05% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Innospec | -23.47% | -18.11% | 3.64% | 75.82% | 598.46% | 905.43% |
| Chemours | -32.67% | -66.72% | -41.82% | 14.99% | -41.49% | -41.49% |
Performance & Financial Health Analysis: Innospec vs Chemours
| Metric | IOSP | CC |
|---|---|---|
| Market Information | ||
| Market Cap | $1.99B | $1.80B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 234,810 | 4,582,450 |
| 90 Day Avg. Volume | 227,103 | 4,943,027 |
| Last Close | $81.44 | $12.19 |
| 52 Week Range | $74.10 - $128.35 | $9.13 - $22.38 |
| % from 52W High | -36.55% | -45.53% |
| All-Time High | $133.71 (May 06, 2024) | $58.08 (Oct 23, 2017) |
| % from All-Time High | -39.09% | -79.01% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | 0.05% |
| Quarterly Earnings Growth | -0.25% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | -0.07% |
| Operating Margin (TTM) | 0.08% | -0.13% |
| Return on Equity (TTM) | 0.02% | -0.88% |
| Debt to Equity (MRQ) | 3.79 | 1,818.41 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $52.19 | $1.58 |
| Cash per Share (MRQ) | $10.69 | $3.35 |
| Operating Cash Flow (TTM) | $136.80M | $258.00M |
| Levered Free Cash Flow (TTM) | $-56,962,500 | $-17,500,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.97% | 6.82% |
| Last 12-Month Dividend | $1.63 | $0.75 |
Valuation & Enterprise Metrics Analysis: Innospec vs Chemours
| Metric | IOSP | CC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 102.32 | 67.83 |
| Forward P/E | 12.75 | 5.19 |
| PEG Ratio | 12.75 | 5.19 |
| Price to Sales (TTM) | 1.11 | 0.31 |
| Price to Book (MRQ) | 1.53 | 7.58 |
| Market Capitalization | ||
| Market Capitalization | $1.99B | $1.80B |
| Enterprise Value | $1.77B | $5.64B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.99 | 0.96 |
| Enterprise to EBITDA | 28.64 | 15.01 |
| Risk & Other Metrics | ||
| Beta | N/A | N/A |
| Book Value per Share (MRQ) | $52.19 | $1.58 |
Financial Statements Comparison: Innospec vs Chemours
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IOSP | CC |
|---|---|---|
| Revenue/Sales | $440.80M | $1.37B |
| Cost of Goods Sold | $315.70M | $1.13B |
| Gross Profit | $125.10M | $236.00M |
| Research & Development | $12.70M | $27.00M |
| Operating Income (EBIT) | $43.00M | $78.00M |
| EBITDA | $54.10M | $181.00M |
| Pre-Tax Income | $44.40M | $0 |
| Income Tax | $11.60M | $4.00M |
| Net Income (Profit) | $32.80M | $-4.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IOSP | CC |
|---|---|---|
| Cash & Equivalents | $299.80M | $464.00M |
| Total Current Assets | $977.10M | $2.93B |
| Total Current Liabilities | $357.60M | $1.67B |
| Long-Term Debt | $30.40M | $4.28B |
| Total Shareholders Equity | $1.27B | $580.00M |
| Retained Earnings | $1.06B | $1.66B |
| Property, Plant & Equipment | $321.50M | $8.30B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IOSP | CC |
|---|---|---|
| Operating Cash Flow | $21.70M | $-104.00M |
| Capital Expenditures | $100,000 | $-84.00M |
| Free Cash Flow | $12.70M | $-196.00M |
| Debt Repayment | N/A | $-46.00M |
| Common Stock Repurchase | $-4.80M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IOSP | CC |
|---|---|---|
| Shares Short | 260,930 | 16.00M |
| Short Ratio | 1.09 | 3.05 |
| Short % of Float | 0.01% | 0.16% |
| Average Daily Volume (10 Day) | 234,810 | 4,582,450 |
| Average Daily Volume (90 Day) | 227,103 | 4,943,027 |
| Shares Outstanding | 24.96M | 149.43M |
| Float Shares | 24.63M | 139.95M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.00% | 0.99% |
Dividend Analysis & Yield Comparison: Innospec vs Chemours
| Metric | IOSP | CC |
|---|---|---|
| Last 12-Month Dividend | $1.63 | $0.75 |
| Last 12-Month Dividend Yield | 1.97% | 6.82% |
| 3-Year Avg Annual Dividend | $1.48 | $0.83 |
| 3-Year Avg Dividend Yield | 0.70% | 1.03% |
| 3-Year Total Dividends | $4.45 | $2.50 |
| Ex-Dividend Date | May 20, 2025 | Feb 28, 2025 |